Lipid Market to reach $23.8 Bn by 2032, Says Global Market Insights Inc.
09 janv. 2024 19h00 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The lipid market valuation is estimated to surpass USD 23.8 billion by 2032, as reported in a research study by Global Market Insights...
BioJiva Reports Results of Pilot Phase 2 Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
15 sept. 2022 07h00 HE
|
BioJiva, LLC
Signals of Clinical Benefit Detected in Small Phase 2 Study, Suggesting Potential to Show Statistically Significant Therapeutic Benefit in Larger, Targeted TrialConsistent Benefit vs. Placebo in...
Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit
19 oct. 2021 07h00 HE
|
Retrotope
Data Demonstrate RT011 Offers Dose-Dependent Protection Against Retinal Lipid Peroxidation (LPO) and Cell Damage, as well as Preservation of Visual Function Findings Provide Rationale for Advancement...
Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)
06 oct. 2021 07h00 HE
|
Retrotope
Treatment with RT001 Results in Statistically Significant Improvements in Overall Survival and Progression Free Survival for INAD Patients as Compared to Control Benefits Supported by Totality of...
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)
11 août 2021 07h00 HE
|
Retrotope
LOS ALTOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)
30 juin 2021 07h00 HE
|
Retrotope
LOS ALTOS, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
21 avr. 2021 07h00 HE
|
Retrotope
LOS ALTOS, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...